147 related articles for article (PubMed ID: 32037915)
1. Grade 3A follicular lymphoma can be effectively controlled with very low-dose radiation therapy.
Imber BS; Chau K; Goldberg E; Joffe E; Yahalom J
Leuk Lymphoma; 2020 Jun; 61(6):1500-1503. PubMed ID: 32037915
[No Abstract] [Full Text] [Related]
2. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
[TBL] [Abstract][Full Text] [Related]
3. Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG.
Binkley MS; Brady JL; Hajj C; Chelius M; Chau K; Balogh A; Levis M; Filippi AR; Jones M; Ahmed S; MacManus M; Wirth A; Oguchi M; Vistisen AK; Andraos TY; Ng AK; Aleman BMP; Choi SH; Kirova YM; Hardy S; Reinartz G; Eich HT; Bratman SV; Constine LS; Suh CO; Dabaja B; El-Galaly TC; Hodgson DC; Ricardi U; Yahalom J; Mikhaeel NG; Hoppe RT
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):522-529. PubMed ID: 30858143
[TBL] [Abstract][Full Text] [Related]
4. First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis.
Pouyiourou M; Meyer A; Stroux A; Viardot A; La Rosée P; Maschmeyer G; Kämpfe D; Kahl C; Vucinic V; Monecke A; Hirt C; Weber T; Meissner J; Witzens-Harig M; Böttcher S; Schmalenberg H; Marks R; Prange-Krex G; Kroschinsky F; Hauf E; Keller U; Koch K; Klapper W; Herold M; Scholz CW;
Ann Hematol; 2020 Dec; 99(12):2821-2829. PubMed ID: 32734548
[TBL] [Abstract][Full Text] [Related]
5. Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma.
König L; Herfarth K; Hörner-Rieber J; Dietrich S; Wiegel T; Debus J; Viardot A
Strahlenther Onkol; 2020 Aug; 196(8):705-714. PubMed ID: 32377821
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy.
Maeshima AM; Taniguchi H; Nomoto J; Miyamoto K; Fukuhara S; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Hum Pathol; 2013 Nov; 44(11):2529-35. PubMed ID: 23916290
[TBL] [Abstract][Full Text] [Related]
7. [Low grade lymphoma: research progress and questions about treatment].
Ishizawa K
Rinsho Ketsueki; 2015 Oct; 56(10):2039-46. PubMed ID: 26458443
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of first-line (131)I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic (18)F-fluorodeoxyglucose positron emission tomography.
McQuillan AD; Macdonald WB; Turner JH
Leuk Lymphoma; 2015 May; 56(5):1271-7. PubMed ID: 25065701
[TBL] [Abstract][Full Text] [Related]
9. Radiation therapy for localized duodenal low-grade follicular lymphoma.
Harada A; Oguchi M; Terui Y; Takeuchi K; Igarashi M; Kozuka T; Harada K; Uno T; Hatake K
J Radiat Res; 2016 Jul; 57(4):412-7. PubMed ID: 27009323
[TBL] [Abstract][Full Text] [Related]
10. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.
Ardeshna KM; Qian W; Smith P; Braganca N; Lowry L; Patrick P; Warden J; Stevens L; Pocock CF; Miall F; Cunningham D; Davies J; Jack A; Stephens R; Walewski J; Ferhanoglu B; Bradstock K; Linch DC
Lancet Oncol; 2014 Apr; 15(4):424-35. PubMed ID: 24602760
[TBL] [Abstract][Full Text] [Related]
11. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.
Ruella M; Filippi AR; Bruna R; Di Russo A; Magni M; Caracciolo D; Passera R; Matteucci P; Di Nicola M; Corradini P; Parvis G; Gini G; Olivieri A; Ladetto M; Ricardi U; Tarella C; Devizzi L
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):783-91. PubMed ID: 26972651
[TBL] [Abstract][Full Text] [Related]
12. Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era.
Mustafa Ali M; Rybicki L; Nomani L; Rouphail B; Dean RM; Hill BT; Jagadeesh D; Pohlman B; Hsi ED; Smith MR
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):797-803. PubMed ID: 28789937
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy for stage I/II follicular lymphoma (FL): is it time for a re-appraisal?
Mondello P; Steiner N; Wasle I; Pitini V; Mian M
Anticancer Res; 2014 Nov; 34(11):6701-4. PubMed ID: 25368277
[TBL] [Abstract][Full Text] [Related]
14. Follicular lymphoma grade 3: review and updates.
Vaidyanathan G; Czuczman MS
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):431-5. PubMed ID: 25066038
[TBL] [Abstract][Full Text] [Related]
15. Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles.
Horn H; Schmelter C; Leich E; Salaverria I; Katzenberger T; Ott MM; Kalla J; Romero M; Siebert R; Rosenwald A; Ott G
Haematologica; 2011 Sep; 96(9):1327-34. PubMed ID: 21659362
[TBL] [Abstract][Full Text] [Related]
16. Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy.
Yuan J; Greiner TC; Fu K; Smith LM; Aoun P; Chan WC; Bierman PJ; Bociek RG; Vose JM; Armitage JO; Weisenburger DD
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):488-497.e2. PubMed ID: 28842137
[TBL] [Abstract][Full Text] [Related]
17. Early stage W.H.O. grade I and II follicular lymphoma treated with radiation therapy alone.
Ahmed N; Owen TE; Rubinger M; Williams G; Nugent Z; Ahmed S; Cooke A
PLoS One; 2013; 8(6):e65156. PubMed ID: 23762303
[TBL] [Abstract][Full Text] [Related]
18. R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.
Barr PM; Li H; Burack WR; LeBlanc M; Smith SM; Gopal AK; Floyd JD; Persky DO; Press OW; Fisher RI; Friedberg JW
Lancet Haematol; 2018 Mar; 5(3):e102-e108. PubMed ID: 29396094
[TBL] [Abstract][Full Text] [Related]
19. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL.
Koch K; Hoster E; Ziepert M; Unterhalt M; Ott G; Rosenwald A; Hansmann ML; Bernd W; Stein H; Pöschel V; Dreyling M; Trümper L; Löffler M; Schmitz N; Hiddemann W; Pfreundschuh M; Klapper W
Ann Oncol; 2016 Jul; 27(7):1323-9. PubMed ID: 27117536
[TBL] [Abstract][Full Text] [Related]
20. Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy.
Wahlin BE; Sundström C; Sander B; Christensson B; Jeppsson-Ahlberg Å; Hjalmarsson E; Holte H; Østenstad B; Brown PD; Smeland EB; Kimby E
Leuk Lymphoma; 2014 Feb; 55(2):288-95. PubMed ID: 23662992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
